Therapeutic Mechanisms of Lithium in Bipolar Disorder: Recent Advances and Current Understanding

CNS Drugs

Volumn 30, Issue 10, 2016, Pages 931-949

  Malhi, Gin S ^a,b,c   Outhred, Tim ^a,b,c  

^a St George Hospital and Community Health Service   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c ROYAL NORTH SHORE HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID; 4 AMINOBUTYRIC ACID RECEPTOR; ACETYLCHOLINE; ADENYLATE CYCLASE; BRAIN DERIVED NEUROTROPHIC FACTOR; CALCIUM; CYCLIC AMP; DOPAMINE; DOPAMINE RECEPTOR; G PROTEIN COUPLED RECEPTOR; GLUTAMIC ACID; GLYCINE; GLYCOGEN SYNTHASE KINASE 3BETA; LITHIUM; MARCKS PROTEIN; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NEUROTROPHIC FACTOR; PHOSPHATIDYLINOSITIDE; PROTEIN KINASE C; GSK3B PROTEIN, HUMAN; LITHIUM DERIVATIVE; TRANQUILIZER;

AEROBIC METABOLISM; ANIMAL MODEL; ANTIOXIDANT ACTIVITY; APOPTOSIS; BIPOLAR DISORDER; CALCIUM CELL LEVEL; CELL STRUCTURE; CIRCADIAN RHYTHM; CLINICAL PRACTICE; COGNITION; CONNECTOME; DRUG EFFECT; DRUG MECHANISM; DRUG RESPONSE; ENZYME INHIBITION; GLIA; HUMAN; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; NEUROMODULATION; NEUROPROTECTION; NEUROTRANSMISSION; NONHUMAN; PHARMACOGENETICS; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; REVIEW; SECOND MESSENGER; SYSTEMATIC REVIEW; DRUG EFFECTS; METABOLISM; NERVE CELL NETWORK; OXIDATIVE STRESS; SIGNAL TRANSDUCTION;

ANTIMANIC AGENTS; APOPTOSIS; BIPOLAR DISORDER; GLYCOGEN SYNTHASE KINASE 3 BETA; HUMANS; LITHIUM COMPOUNDS; NERVE NET; OXIDATIVE STRESS; SIGNAL TRANSDUCTION;

EID: 84987644131     PISSN: 11727047     EISSN: 11791934     Source Type: Journal    
DOI: 10.1007/s40263-016-0380-1     Document Type: Review

References (137)

1. Malhi GS, Tanious M, Das P, Coulston CM, Berk M. Potential mechanisms of action of lithium in bipolar disorder. Current understanding. CNS Drugs. 2013;27:135–53.
2. Berk M. Neuroprogression: pathways to progressive brain changes in bipolar disorder. Int J Neuropsychopharmacol. 2009;12:441–5.
3. Berk M, Kapczinski F, Andreazza AC, Dean OM, Giorlando F, Maes M, et al. Pathways underlying neuroprogression in bipolar disorder: focus on inflammation, oxidative stress and neurotrophic factors. Neurosci Biobehav Rev. 2011;35:804–17.
4. Frank E, Nimgaonkar VL, Phillips ML, Kupfer DJ. All the world’s a (clinical) stage: rethinking bipolar disorder from a longitudinal perspective. Mol Psychiatry. 2015;20:23–31.
5. Hajek T, Bauer M, Simhandl C, Rybakowski J, O’Donovan C, Pfennig A, et al. Neuroprotective effect of lithium on hippocampal volumes in bipolar disorder independent of long-term treatment response. Psychol Med. 2014;44:507–17.
6. Insel TR. The NIMH Research Domain Criteria (RDoC) project: precision medicine for psychiatry. Am J Psychiatry. 2014;171:395–7.
7. Zohar J, Stahl S, Möller H-J, Blier P, Kupfer D, Yamawaki S, et al. A review of the current nomenclature for psychotropic agents and an introduction to the neuroscience-based nomenclature. Eur Neuropsychopharmacol. 2015;25:2318–25.
8. Gershon S, Chengappa KR, Malhi GS. Lithium specificity in bipolar illness: a classic agent for the classic disorder. Bipolar Disord. 2009;11:34–44.
9. Malhi GS, Porter RJ. Are ‘buy-polar’ forces and “try-polar” thinking expanding bipolarity? Aust N Z J Psychiatry. 2014;48:697–700.
10. Malhi GS, Berk M. Diagnosing bipolar disorder: defining thresholds and setting boundaries. Aust N Z J Psychiatry. 2014;48:500–4.
11. Malhi GS, Das P, Gessler D, Outhred T, Fritz K. The mixed features of DSM-5. Aust N Z J Psychiatry. 2015;49:842–3.
12. Sara GE, Malhi GS. Trends in diagnosis of bipolar disorder: have the boundaries changed? Aust N Z J Psychiatry. 2015;49:1021–8.
13. Malhi GS, Geddes JR. Carving bipolarity using a lithium sword. Br J Psychiatry. 2014;205:337–9.
14. Geddes JR, Goodwin GM, Rendell J, Azorin J-M, Cipriani A, Ostacher MJ, et al. Lithium plus valproate combination therapy versus monotherapy for relapse prevention in bipolar I disorder (BALANCE): a randomised open-label trial. Lancet. 2010;375:385–95.
15. Simhandl C, König B, Amann BL. A prospective 4-year naturalistic follow-up of treatment and outcome of 300 bipolar I and II patients. J Clin Psychiatry. 2014;75:254–62 (quiz 263).
16. Benedetti F, Bollettini I, Barberi I, Radaelli D, Poletti S, Locatelli C, et al. Lithium and GSK3-β promoter gene variants influence white matter microstructure in bipolar disorder. Neuropsychopharmacology. 2013;38:313–27.
17. Iwahashi K, Nishizawa D, Narita S, Numajiri M, Murayama O, Yoshihara E, et al. Haplotype analysis of GSK-3β gene polymorphisms in bipolar disorder lithium responders and nonresponders. Clin Neuropharmacol. 2014;37:108–10.
18. Jang Y, Lee SH, Lee B, Jung S, Khalid A, Uchida K, et al. TRPM2, a susceptibility gene for bipolar disorder, regulates glycogen synthase kinase-3 activity in the brain. J Neurosci. 2015;35:11811–23.
19. de Sousa RT, Zanetti MV, Talib LL, Serpa MH, Chaim TM, Carvalho AF, et al. Lithium increases platelet serine-9 phosphorylated GSK-3β levels in drug-free bipolar disorder during depressive episodes. J Psychiatr Res. 2015;62:78–83.
20. Lin Y-F, Huang M-C, Liu H-C. Glycogen synthase kinase 3β gene polymorphisms may be associated with bipolar I disorder and the therapeutic response to lithium. J Affect Disord. 2013;147:401–6.
21. Caberlotto L, Carboni L, Zanderigo F, Andreetta F, Andreoli M, Gentile G, et al. Differential effects of glycogen synthase kinase 3 (GSK3) inhibition by lithium or selective inhibitors in the central nervous system. Naunyn Schmiedeberg’s Arch Pharmacol. 2013;386:893–903.
22. Kinoshita C, Miyazaki K, Ishida N. Chronic stress affects PERIOD2 expression through glycogen synthase kinase-3β phosphorylation in the central clock. NeuroReport. 2012;23:98–102.
23. Tian N, Kanno T, Jin Y, Nishizaki T. Lithium potentiates GSK-3β activity by inhibiting phosphoinositide 3-kinase-mediated Akt phosphorylation. Biochem Biophys Res Commun. 2014;450:746–9.
24. Harrison LM, Muller SH, Spano D. Effects of the Ras homolog Rhes on Akt/protein kinase B and glycogen synthase kinase 3 phosphorylation in striatum. Neuroscience. 2013;236:21–30.
25. Wu J, Zhu D, Zhang J, Li G, Liu Z, Sun J. Lithium protects against methamphetamine-induced neurotoxicity in PC12 cells via Akt/GSK3β/mTOR pathway. Biochem Biophys Res Commun. 2015;465:368–73.
26. Emamghoreishi M, Keshavarz M, Nekooeian AA. Acute and chronic effects of lithium on BDNF and GDNF mRNA and protein levels in rat primary neuronal, astroglial and neuroastroglia cultures. Iran J Basic Med Sci. 2015;18:240–6.
27. Tunca Z, Ozerdem A, Ceylan D, Yalçın Y, Can G, Resmi H, et al. Alterations in BDNF (brain derived neurotrophic factor) and GDNF (glial cell line-derived neurotrophic factor) serum levels in bipolar disorder: the role of lithium. J Affect Disord. 2014;166:193–200.
28. Stertz L, Fries GR, Aguiar BW de, Pfaffenseller B, Valvassori SS, Gubert C, et al. Histone deacetylase activity and brain-derived neurotrophic factor (BDNF) levels in a pharmacological model of mania. Rev Bras Psiquiatr. 2014;36:39–46.
29. Moghadas M, Edalatmanesh MA. Protective effect of lithium chloride against trimethyltin-induced hippocampal degeneration and comorbid depression in rats. Comp Clin Pathol. 2014;24:1165–75.
30. Sharma S, Taliyan R. Synergistic effects of GSK-3β and HDAC inhibitors in intracerebroventricular streptozotocin-induced cognitive deficits in rats. Naunyn Schmiedeberg’s Arch Pharmacol. 2014;388:337–49.
31. Croce N, Mathé AA, Gelfo F, Caltagirone C, Bernardini S, Angelucci F. Effects of lithium and valproic acid on BDNF protein and gene expression in an in vitro human neuron-like model of degeneration. J Psychopharmacol. 2014;28:964–72.
32. Ricken R, Adli M, Lange C, Krusche E, Stamm TJ, Gaus S, et al. Brain-derived neurotrophic factor serum concentrations in acute depressive patients increase during lithium augmentation of antidepressants. J Clin Psychopharmacol. 2013;33:806–9.
33. Hing B, Davidson S, Lear M, Breen G, Quinn J, McGuffin P, et al. A polymorphism associated with depressive disorders differentially regulates brain derived neurotrophic factor promoter IV activity. Biol Psychiatry. 2012;71:618–26.
34. Dwivedi T, Zhang H. Lithium-induced neuroprotection is associated with epigenetic modification of specific BDNF gene promoter and altered expression of apoptotic-regulatory proteins. Front Neurosci. 2015;8:525.
35. da-Rosa DD, Valvassori SS, Steckert AV, Ornell F, Ferreira CL, Lopes-Borges J, et al. Effects of lithium and valproate on oxidative stress and behavioral changes induced by administration of m-AMPH. Psychiatry Res. 2012;198:521–6.
36. Macêdo DS, de Lucena DF, Queiroz AIG, Cordeiro RC, Araújo MM, Sousa FC, et al. Effects of lithium on oxidative stress and behavioral alterations induced by lisdexamfetamine dimesylate: relevance as an animal model of mania. Prog Neuropsychopharmacol Biol Psychiatry. 2013;43:230–7.
37. Toledano E, Ogryzko V, Danchin A, Ladant D, Mechold U. 3′-5′ Phosphoadenosine phosphate is an inhibitor of PARP-1 and a potential mediator of the lithium-dependent inhibition of PARP-1 in vivo. Biochem J. 2012;443:485–90.
38. Huzayyin AA, Andreazza AC, Turecki G, Cruceanu C, Rouleau GA, Alda M, et al. Decreased global methylation in patients with bipolar disorder who respond to lithium. Int J Neuropsychopharmacol. 2014;17:561–9.
39. Farah R, Khamisy-Farah R, Amit T, Youdim MBH, Arraf Z. Lithium’s gene expression profile, relevance to neuroprotection A cDNA microarray study. Cell Mol Neurobiol. 2013;33:411–20.
40. Nciri R, Desmoulin F, Allagui MS, Murat J-C, Feki AE, Vincent C, et al. Neuroprotective effects of chronic exposure of SH-SY5Y to low lithium concentration involve glycolysis stimulation, extracellular pyruvate accumulation and resistance to oxidative stress. Int J Neuropsychopharmacol. 2013;16:365–76.
41. Wang H-M, Zhang T, Li Q, Huang J-K, Chen R-F, Sun X-J. Inhibition of glycogen synthase kinase-3β by lithium chloride suppresses 6-hydroxydopamine-induced inflammatory response in primary cultured astrocytes. Neurochem Int. 2013;63:345–53.
42. Watanabe S, Iga J, Nishi A, Numata S, Kinoshita M, Kikuchi K, et al. Microarray analysis of global gene expression in leukocytes following lithium treatment. Hum Psychopharmacol. 2014;29:190–8.
43. Khairova R, Pawar R, Salvadore G, Juruena MF, de Sousa RT, Soeiro-de-Souza MG, et al. Effects of lithium on oxidative stress parameters in healthy subjects. Mol Med Rep. 2012;5:680–2.
44. Gawlik-Kotelnicka O, Mielicki W, Rabe-Jabłońska J, Lazarek J, Strzelecki D. Impact of lithium alone or in combination with haloperidol on oxidative stress parameters and cell viability in SH-SY5Y cell culture. Acta Neuropsychiatrica. 2016;28:38–44.
45. Banerjee U, Dasgupta A, Rout JK, Singh OP. Effects of lithium therapy on Na+-K+-ATPase activity and lipid peroxidation in bipolar disorder. Prog Neuropsychopharmacol Biol Psychiatry. 2012;37:56–61.
46. de Sousa RT, Zarate CA, Zanetti MV, Costa AC, Talib LL, Gattaz WF, et al. Oxidative stress in early stage bipolar disorder and the association with response to lithium. J Psychiatr Res. 2014;50:36–41.
47. Tan H, Young LT, Shao L, Che Y, Honer WG, Wang J-F. Mood stabilizer lithium inhibits amphetamine-increased 4-hydroxynonenal-protein adducts in rat frontal cortex. Int J Neuropsychopharmacol. 2012;15:1275–85.
48. de Sousa RT, Streck EL, Zanetti MV, Ferreira GK, Diniz BS, Brunoni AR, et al. Lithium increases leukocyte mitochondrial complex I activity in bipolar disorder during depressive episodes. Psychopharmacology. 2015;232:245–50.
49. Rizak J, Tan H, Zhu H, Wang JF. Chronic treatment with the mood-stabilizing drug lithium up-regulates nuclear factor E2-related factor 2 in rat pheochromocytoma PC12 cells in vitro. Neuroscience. 2014;256:223–9.
50. Alural B, Ozerdem A, Allmer J, Genc K, Genc S. Lithium protects against paraquat neurotoxicity by NRF2 activation and miR-34a inhibition in SH-SY5Y cells. Front Cell Neurosci. 2015;9:209.
51. de Souza Gomes JA, de Souza GC, Berk M, Cavalcante LM, de Sousa FCF, Budni J, et al. Antimanic-like activity of candesartan in mice: possible involvement of antioxidant, anti-inflammatory and neurotrophic mechanisms. Eur Neuropsychopharmacol. 2015;25:2086–97.
52. Liechti FD, Stüdle N, Theurillat R, Grandgirard D, Thormann W, Leib SL. The mood-stabilizer lithium prevents hippocampal apoptosis and improves spatial memory in experimental meningitis. PLoS One. 2014;9:e113607.
53. Tanno M, Kuno A, Ishikawa S, Miki T, Kouzu H, Yano T, et al. Translocation of glycogen synthase kinase-3β (GSK-3β), a trigger of permeability transition, is kinase activity-dependent and mediated by interaction with voltage-dependent anion channel 2 (VDAC2). J Biol Chem. 2014;289:29285–96.
54. Ngok-Ngam P, Watcharasit P, Thiantanawat A, Satayavivad J. Pharmacological inhibition of GSK3 attenuates DNA damage-induced apoptosis via reduction of p53 mitochondrial translocation and Bax oligomerization in neuroblastoma SH-SY5Y cells. Cell Mol Biol Lett. 2013;18:58–74.
55. Keshavarz M, Emamghoreishi M, Nekooeian AA, Warsh J, Zare HR. Increased bcl-2 protein levels in rat primary astrocyte culture following chronic lithium treatment. Iran J Med Sci. 2013;38:255–62.
56. Beech RD, Leffert JJ, Lin A, Sylvia LG, Umlauf S, Mane S, et al. Gene-expression differences in peripheral blood between lithium responders and non-responders in the Lithium Treatment-Moderate dose Use Study (LiTMUS). Pharmacogenomics J. 2013;14:182–91.
57. Gupta A, Schulze TG, Nagarajan V, Akula N, Corona W, Jiang X-Y, et al. Interaction networks of lithium and valproate molecular targets reveal a striking enrichment of apoptosis functional clusters and neurotrophin signaling. Pharmacogenomics J. 2012;12:328–41.
58. Hou L, Xiong N, Liu L, Huang J, Han C, Zhang G, et al. Lithium protects dopaminergic cells from rotenone toxicity via autophagy enhancement. BMC Neurosci. 2015;16:82.
59. Milanesi E, Hadar A, Maffioletti E, Werner H, Shomron N, Gennarelli M, et al. Insulin-like growth factor 1 differentially affects lithium sensitivity of lymphoblastoid cell lines from lithium responder and non-responder bipolar disorder patients. J Mol Neurosci. 2015;56:681–7.
60. Squassina A, Costa M, Congiu D, Manchia M, Angius A, Deiana V, et al. Insulin-like growth factor 1 (IGF-1) expression is up-regulated in lymphoblastoid cell lines of lithium responsive bipolar disorder patients. Pharmacol Res. 2013;73:1–7.
61. Ferensztajn-Rochowiak E, Rybakowski JK. The effect of lithium on hematopoietic, mesenchymal and neural stem cells. Pharmacol Rep. 2016;68:224–30.
62. Rajkowska G, Clarke G, Mahajan G, Licht CM, van de Werd HJ, Yuan P, et al. Differential effect of lithium on cell number in the hippocampus and prefrontal cortex in adult mice: a stereological study. Bipolar Disord. 2016;18:41–51.
63. Kara N, Narayanan S, Belmaker RH, Einat H, Vaidya VA, Agam G. Chronic lithium treatment enhances the number of quiescent neural progenitors but not the number of DCX-positive immature neurons. Int J Neuropsychopharmacol. 2015;18:pyv003–3.
64. Meffre D, Massaad C, Grenier J. Lithium chloride stimulates PLP and MBP expression in oligodendrocytes via Wnt/β-catenin and Akt/CREB pathways. Neuroscience. 2015;284:962–71.
65. Nciri R, Boujbiha MA, Jbahi S, Allagui MS, Elfeki A, Vincent C, et al. Cytoskeleton involvement in lithium-induced SH-SY5Y neuritogenesis and the role of glycogen synthase kinase 3β. Aging Clin Exp Res. 2015;27:255–63.
66. Calabrese B, Halpain S. Lithium prevents aberrant NMDA-induced F-actin reorganization in neurons. NeuroReport. 2014;25:1331–7.
67. de Bartolomeis A, Tomasetti C, Cicale M, Yuan P-X, Manji HK. Chronic treatment with lithium or valproate modulates the expression of Homer1b/c and its related genes Shank and Inositol 1,4,5-trisphosphate receptor. Eur Neuropsychopharmacol. 2012;22:527–35.
68. Dong H, Zhang X, Dai X, Lu S, Gui B, Jin W, et al. Lithium ameliorates lipopolysaccharide-induced microglial activation via inhibition of toll-like receptor 4 expression by activating the PI3K/Akt/FoxO1 pathway. J Neuroinflamm. 2014;11:140.
69. Yu Z, Ono C, Aiba S, Kikuchi Y, Sora I, Matsuoka H, et al. Therapeutic concentration of lithium stimulates complement C3 production in dendritic cells and microglia via GSK-3 inhibition. Glia. 2015;63:257–70.
70. Sarkar S, Floto RA, Berger Z, Imarisio S, Cordenier A, Pasco M, et al. Lithium induces autophagy by inhibiting inositol monophosphatase. J Cell Biol. 2005;170:1101–11.
71. Damri O, Sade Y, Toker L, Bersudsky Y, Belmaker RH, Agam G, et al. Molecular effects of lithium are partially mimicked by inositol-monophosphatase (IMPA)1 knockout mice in a brain region-dependent manner. Eur Neuropsychopharmacol. 2015;25:425–34.
72. Shtein L, Agam G, Belmaker RH, Bersudsky Y. Inositol-deficient food augments a behavioral effect of long-term lithium treatment mediated by inositol monophosphatase inhibition: an animal model with relevance for bipolar disorder. J Clin Psychopharmacol. 2015;35:175–7.
73. Toker L, Bersudsky Y, Plaschkes I, Chalifa-Caspi V, Berry GT, Buccafusca R, et al. Inositol-related gene knockouts mimic lithium’s effect on mitochondrial function. Neuropsychopharmacology. 2014;39:319–28.
74. Machado-Vieira R, Gattaz WF, Zanetti MV, de Sousa RT, Carvalho AF, Soeiro-de-Souza MG, et al. A longitudinal (6-week) 3T (1)H-MRS study on the effects of lithium treatment on anterior cingulate cortex metabolites in bipolar depression. Eur Neuropsychopharmacol. 2015;25:2311–7.
75. Agam G, Almog O. Calbindin D28k and S100B have a similar interaction site with the lithium-inhibitable enzyme inositol monophosphatase-1: a new drug target site. J Med Chem. 2015;58:2042–4.
76. Singh N, Halliday AC, Thomas JM, Kuznetsova OV, Baldwin R, Woon ECY, et al. A safe lithium mimetic for bipolar disorder. Nat Commun. 2013;4:1332.
77. Singh N, Sharpley AL, Emir UE, Masaki C, Herzallah MM, Gluck MA, et al. Effect of the putative lithium mimetic ebselen on brain myo-inositol, sleep, and emotional processing in humans. Neuropsychopharmacology. 2016;41:1768–78.
78. Song J, Bergen SE, Di Florio A, Karlsson R, Charney A, Ruderfer DM, et al. Genome-wide association study identifies SESTD1 as a novel risk gene for lithium-responsive bipolar disorder. Mol Psychiatry. 2015:1–8.
79. Tsui MMK, Tai WCS, Wong WY, Hsiao WLW. Selective G2/M arrest in a p53Val135-transformed cell line induced by lithium is mediated through an intricate network of MAPK and β-catenin signaling pathways. Life Sci. 2012;91:312–21.
80. Cechinel-Recco K, Valvassori SS, Varela RB, Resende WR, Arent CO, Vitto MF, et al. Lithium and tamoxifen modulate cellular plasticity cascades in animal model of mania. J Psychopharmacol. 2012;26:1594–604.
81. Kovzun EI, Lukashenya OS, Pushkarev VM, Mikosha AS, Tron’ko ND. Effect of ions of potassium and lithium on NO synthase expression in the human adrenal cortex. Bull Exp Biol Med. 2014;156:332–4.
82. Deshauer D, Grof E, Alda M, Grof P. Patterns of DST positivity in remitted affective disorders. Biol Psychiatry. 1999;45:1023–9.
83. Zaeri S, Farjadian S, Emamghoreishi M. Decreased levels of canonical transient receptor potential channel 3 protein in the rat cerebral cortex after chronic treatment with lithium or valproate. Res Pharm Sci. 2015;10:397–406.
84. McCarthy MJ, Le Roux MJ, Wei H, Beesley S, Kelsoe JR, Welsh DK. Calcium channel genes associated with bipolar disorder modulate lithium’s amplification of circadian rhythms. Neuropharmacology. 2015;101:439–48.
85. Heinrich A, von der Heyde AS, Böer U, Phu DT, Tzvetkov M, Oetjen E. Lithium enhances CRTC oligomer formation and the interaction between the CREB coactivators CRTC and CBP–implications for CREB-dependent gene transcription. Cell Signal. 2013;25:113–25.
86. Mavrikaki M, Schintu N, Kastellakis A, Nomikos GG, Svenningsson P, Panagis G. Effects of lithium and aripiprazole on brain stimulation reward and neuroplasticity markers in the limbic forebrain. Eur Neuropsychopharmacol. 2014;24:630–8.
87. Alda M, Shao L, Wang J-F, Lopez de Lara C, Jaitovich-Groisman I, Lebel V, et al. Alterations in phosphorylated cAMP response element-binding protein (pCREB) signaling: an endophenotype of lithium-responsive bipolar disorder? Bipolar Disord. 2013;15:824–31.
88. Lueke K, Kaiser T, Svetlitchny A, Welzel O, Wenzel EM, Tyagarajan S, et al. Basic presynaptic functions in hippocampal neurons are not affected by acute or chronic lithium treatment. J Neural Transm. 2014;121:211–9.
89. Cruceanu C, Alda M, Grof P, Rouleau GA, Turecki G. Synapsin II is involved in the molecular pathway of lithium treatment in bipolar disorder. PLoS One. 2012;7:e32680.
90. Wakita M, Nagami H, Takase Y, Nakanishi R, Kotani N, Akaike N. Modifications of excitatory and inhibitory transmission in rat hippocampal pyramidal neurons by acute lithium treatment. Brain Res Bull. 2015;117:39–44.
91. Higgins GA, Allyn-Feuer A, Barbour E, Athey BD. A glutamatergic network mediates lithium response in bipolar disorder as defined by epigenome pathway analysis. Pharmacogenomics. 2015;16:1547–63.
92. Zanetti MV, Otaduy MC, de Sousa RT, Gattaz WF, Busatto GF, Leite CC, et al. Bimodal effect of lithium plasma levels on hippocampal glutamate concentrations in bipolar II depression: a pilot study. Int J Neuropsychopharmacol. 2015;18:pyu058–8.
93. Ghasemi M, Dehpour AR. The NMDA receptor/nitric oxide pathway: a target for the therapeutic and toxic effects of lithium. Trends Pharmacol Sci. 2011;32:420–34.
94. Chen C-H, Lee C-S, Lee M-TM, Ouyang W-C, Chen C-C, Chong M-Y, et al. Variant GADL1 and response to lithium therapy in bipolar I disorder. N Engl J Med. 2014;370:119–28.
95. Hou L, Heilbronner U, Degenhardt F, Adli M, Akiyama K, Akula N, et al. Genetic variants associated with response to lithium treatment in bipolar disorder: a genome-wide association study. Lancet. 2016;387:1085–93.
96. Birnbaum R, Shin JH. Variant GADL1 and response to lithium in bipolar I disorder. N Engl J Med. 2014;370:1855–60.
97. Ago Y, Tanaka T, Kita Y, Tokumoto H, Takuma K, Matsuda T. Lithium attenuates methamphetamine-induced hyperlocomotion and behavioral sensitization via modulation of prefrontal monoamine release. Neuropharmacology. 2012;62:1634–9.
98. van Enkhuizen J, Milienne-Petiot M, Geyer MA, Young JW. Modeling bipolar disorder in mice by increasing acetylcholine or dopamine: chronic lithium treats most, but not all features. Psychopharmacology. 2015;232:3455–67.
99. Marchese G, Scheggi S, Secci ME, De Montis MG, Gambarana C. Anti-anhedonic activity of long-term lithium treatment in rats exposed to repeated unavoidable stress. Int J Neuropsychopharmacol. 2013;16:1611–21.
100. Del’ Guidice T, Beaulieu J-M. Selective disruption of dopamine D2-receptors/beta-arrestin2 signaling by mood stabilizers. J Recept Signal Transduct Res. 2015;35:224–32.
101. Fortin SM, Chartoff EH, Roitman MF. The aversive agent lithium chloride suppresses phasic dopamine release through central GLP-1 receptors. Neuropsychopharmacology. 2016;41:906–15.
102. Farhy Tselnicker I, Tsemakhovich V, Rishal I, Kahanovitch U, Dessauer CW, Dascal N. Dual regulation of G proteins and the G-protein-activated K+ channels by lithium. Proc Natl Acad Sci. 2014;111:5018–23.
103. Jiménez E, Núñez E, Ibáñez I, Zafra F, Aragón C, Giménez C. Glycine transporters GlyT1 and GlyT2 are differentially modulated by glycogen synthase kinase 3β. Neuropharmacology. 2015;89:245–54.
104. McCarthy MJ, Wei H, Marnoy Z, Darvish RM, McPhie DL, Cohen BM, et al. Genetic and clinical factors predict lithium’s effects on PER2 gene expression rhythms in cells from bipolar disorder patients. Transl Psychiatry. 2013;3:e318.
105. McCarthy MJ, Nievergelt CM, Kelsoe JR, Welsh DK. A survey of genomic studies supports association of circadian clock genes with bipolar disorder spectrum illnesses and lithium response. PLoS One. 2012;7:e32091.
106. Schnell A, Sandrelli F, Ranc V, Ripperger JA, Brai E, Alberi L, et al. Mice lacking circadian clock components display different mood-related behaviors and do not respond uniformly to chronic lithium treatment. Chronobiol Int. 2015;32:1075–89.
107. Kittel-Schneider S, Schreck S, Ziegler C, Weißflog L, Hilscher M, Schwarz R, et al. Lithium-induced clock gene expression in lymphoblastoid cells of bipolar affective patients. Pharmacopsychiatry. 2015;48:145–9.
108. Rybakowski JK, Dmitrzak-Weglar M, Kliwicki S, Hauser J. Polymorphism of circadian clock genes and prophylactic lithium response. Bipolar Disord. 2014;16:151–8.
109. Kim SH, Yu HS, Park HG, Ahn YM, Kim YS, Lee YH, et al. Egr1 regulates lithium-induced transcription of the Period 2 (PER2) gene. Biochimica et Biophysica Acta (BBA) Mol Basis Dis. 2013;1832:1969–79.
110. Leussis MP, Berry-Scott EM, Saito M, Jhuang H, de Haan G, Alkan O, et al. The ANK3 bipolar disorder gene regulates psychiatric-related behaviors that are modulated by lithium and stress. Biol Psychiatry. 2013;73:683–90.
111. Malhi GS, Byrow Y, Fritz K, Das P, Baune BT, Porter RJ, et al. Mood disorders: neurocognitive models. Bipolar Disord. 2015;17(Suppl 2):3–20.
112. Malhi GS, McAulay C, Gershon S, Gessler D, Fritz K, Das P, et al. The Lithium Battery: assessing the neurocognitive profile of lithium in bipolar disorder. Bipolar Disord. 2016;18:102–15.
113. Outhred T, Kemp AH, Malhi GS. Physiological correlates of bipolar spectrum disorders and their treatment. In: Kumari V, Boutros N, Bob P, editors. Current topics in behavioral neurosciences. Berlin, Heidelberg: Springer; 2014. p. 47–102.
114. Giakoumatos CI, Nanda P, Mathew IT, Tandon N, Shah J, Bishop JR, et al. Effects of lithium on cortical thickness and hippocampal subfield volumes in psychotic bipolar disorder. J Psychiatr Res. 2015;61:180–7.
115. Hartberg CB, Jørgensen KN, Haukvik UK, Westlye LT, Melle I, Andreassen OA, et al. Lithium treatment and hippocampal subfields and amygdala volumes in bipolar disorder. Bipolar Disord. 2015;17:496–506.
116. Baykara B, Inal-Emiroglu N, Karabay N, Çakmakçı H, Cevher N, Şentürk Pilan B, et al. Increased hippocampal volumes in lithium treated adolescents with bipolar disorders: a structural MRI study. J Affect Disord. 2012;138:433–9.
117. Selek S, Nicoletti M, Zunta-Soares GB, Hatch JP, Nery FG, Matsuo K, et al. A longitudinal study of fronto-limbic brain structures in patients with bipolar I disorder during lithium treatment. J Affect Disord. 2013;150:629–33.
118. Vernon AC, Natesan S, Crum WR, Cooper JD, Modo M, Williams SCR, et al. Contrasting effects of haloperidol and lithium on rodent brain structure: a magnetic resonance imaging study with postmortem confirmation. Biol Psychiatry. 2012;71:855–63.
119. Benedetti F, Poletti S, Radaelli D, Locatelli C, Pirovano A, Lorenzi C, et al. Lithium and GSK-3β promoter gene variants influence cortical gray matter volumes in bipolar disorder. Psychopharmacology. 2015;232:1325–36.
120. Pfennig A, Alda M, Young T, MacQueen G, Rybakowski J, Suwalska A, et al. Prophylactic lithium treatment and cognitive performance in patients with a long history of bipolar illness: no simple answers in complex disease-treatment interplay. Int J Bipolar Disord. 2014;2:1.
121. Hajek T, Cullis J, Novak T, Kopecek M, Hoschl C, Blagdon R, et al. Hippocampal volumes in bipolar disorders: opposing effects of illness burden and lithium treatment. Bipolar Disord. 2012;14:261–70.
122. Berger GE, Wood SJ, Ross M, Hamer CA, Wellard RM, Pell G, et al. Neuroprotective effects of low-dose lithium in individuals at ultra-high risk for psychosis. A longitudinal MRI/MRS study. Curr Pharm Des. 2012;18:570–5.
123. Kessing LV, Forman JL, Andersen PK. Does lithium protect against dementia? Bipolar Disord. 2010;12:87–94.
124. Kessing LV, Sondergard L, Forman JL, Andersen PK. Lithium treatment and risk of dementia. Arch Gen Psychiatry. 2008;65:1331–5.
125. O’Brien WT, Klein PS. Validating GSK3 as an in vivo target of lithium action. Biochem Soc Trans. 2009;37:1133–8.
126. Wei YB, Backlund L, Wegener G, Mathé AA, Lavebratt C. Telomerase dysregulation in the hippocampus of a rat model of depression: normalization by lithium. Int J Neuropsychopharmacol. 2015;18:pyv002.
127. Hayashi A, Le Gal K, Södersten K, Vizlin-Hodzic D, Ågren H, Funa K. Calcium-dependent intracellular signal pathways in primary cultured adipocytes and ANK3 gene variation in patients with bipolar disorder and healthy controls. Mol Psychiatry. 2015;20:931–40.
128. Ferensztajn E, Skibinska M, Kaczmarek M, Losy J, Rybakowski JK. Neurobiology and temperament in the offspring of excellent lithium responders. World J Biol Psychiatry. 2015;16:272–7.
129. Madison JM, Zhou F, Nigam A, Hussain A, Barker DD, Nehme R, et al. Characterization of bipolar disorder patient-specific induced pluripotent stem cells from a family reveals neurodevelopmental and mRNA expression abnormalities. Mol Psychiatry. 2015;20:703–17.
130. Mertens J, Wang Q-W, Kim Y, Yu DX, Pham S, Yang B, et al. Differential responses to lithium in hyperexcitable neurons from patients with bipolar disorder. Nature. 2015;527:95–9.
131. Masaki C, Sharpley AL, Godlewska BR, Berrington A, Hashimoto T, Singh N, et al. Effects of the potential lithium-mimetic, ebselen, on brain neurochemistry: a magnetic resonance spectroscopy study at 7 tesla. Psychopharmacology. 2016;233:1–8.
132. Grof P, Duffy A, Cavazzoni P, Grof E, Garnham J, MacDougall M, et al. Is response to prophylactic lithium a familial trait? J Clin Psychiatry. 2002;63:942–7.
133. Duffy A, Horrocks J, Doucette S, Keown-Stoneman C, McCloskey S, Grof P. The developmental trajectory of bipolar disorder. Br J Psychiatry. 2014;204:122–8.
134. Benedetti F, Dallaspezia S, Lorenzi C, Pirovano A, Radaelli D, Locatelli C, et al. Gene-gene interaction of glycogen synthase kinase 3-β and serotonin transporter on human antidepressant response to sleep deprivation. J Affect Disord. 2012;136:514–9.
135. Tharoor H, Kotambail A, Jain S, Sharma PSVN, Satyamoorthy K. Study of the association of serotonin transporter triallelic 5-HTTLPR and STin2 VNTR polymorphisms with lithium prophylaxis response in bipolar disorder. Psychiatr Genet. 2013;23:77–81.
136. Benedetti F, Bollettini I, Poletti S, Locatelli C, Lorenzi C, Pirovano A, et al. White matter microstructure in bipolar disorder is influenced by the serotonin transporter gene polymorphism 5-HTTLPR. Genes Brain Behav. 2015;14:238–50.
137. Mitjans M, Arias B, Jiménez E, Goikolea JM, Sáiz PA, García-Portilla MP, et al. Exploring genetic variability at PI, GSK3, HPA, and glutamatergic pathways in lithium response: association with IMPA2, INPP1, and GSK3B genes. J Clin Psychopharmacol. 2015;35:600–4.